AR128004A1 - Péptidos antigénicos y métodos para utilizarlos en el diagnóstico de la enfermedad de chagas - Google Patents

Péptidos antigénicos y métodos para utilizarlos en el diagnóstico de la enfermedad de chagas

Info

Publication number
AR128004A1
AR128004A1 ARP220103479A ARP220103479A AR128004A1 AR 128004 A1 AR128004 A1 AR 128004A1 AR P220103479 A ARP220103479 A AR P220103479A AR P220103479 A ARP220103479 A AR P220103479A AR 128004 A1 AR128004 A1 AR 128004A1
Authority
AR
Argentina
Prior art keywords
diagnosis
methods
antigenic peptides
chagas disease
cruzi
Prior art date
Application number
ARP220103479A
Other languages
English (en)
Inventor
Eric Dumonteil
Claudia Herrera
Original Assignee
16
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 16 filed Critical 16
Publication of AR128004A1 publication Critical patent/AR128004A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación proporciona novedosos péptidos antigénicos y mezclas peptídicas, y métodos para utilizarlos en la detección de anticuerpos contra T. cruzi en muestras de tejido y en el diagnóstico de la enfermedad de Chagas en un sujeto.
ARP220103479A 2021-12-17 2022-12-16 Péptidos antigénicos y métodos para utilizarlos en el diagnóstico de la enfermedad de chagas AR128004A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163290972P 2021-12-17 2021-12-17

Publications (1)

Publication Number Publication Date
AR128004A1 true AR128004A1 (es) 2024-03-20

Family

ID=86773571

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103479A AR128004A1 (es) 2021-12-17 2022-12-16 Péptidos antigénicos y métodos para utilizarlos en el diagnóstico de la enfermedad de chagas

Country Status (2)

Country Link
AR (1) AR128004A1 (es)
WO (1) WO2023114960A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117069798B (zh) * 2023-08-21 2024-05-24 南京财经大学 一种抗炎活性的藜麦小肽及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304371A (en) * 1992-02-14 1994-04-19 Lasys Corporation Peptide for diagnosing and immunizing against T. cruzi infection
WO2009099580A2 (en) * 2008-02-05 2009-08-13 Monsanto Technology, Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
US11130994B2 (en) * 2019-12-13 2021-09-28 Autonomous Medical Devices Inc. Automated, cloud-based, point-of-care (POC) pathogen and antibody array detection system and method

Also Published As

Publication number Publication date
WO2023114960A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
CL2022002335A1 (es) Anticuerpos contra sars-cov-2 y métodos para usarlos
CL2021002209A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 202002414)
DOP2019000059A (es) Anticuerpos de unión a cd3
CO2018009434A2 (es) Anticuerpos monoclonales de proteína ns1 anti-virus del dengue
AR082149A1 (es) Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
BR112013003361A2 (pt) anticorpo, polinucleotídeo e polipeptídeo isolado, composição, vetor, célual hospedeira, método de produção de um anticorpo, conjugado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos de tratamento, de indução e de diagnóstico de doença em um indivíduo
AR128004A1 (es) Péptidos antigénicos y métodos para utilizarlos en el diagnóstico de la enfermedad de chagas
EA201991005A1 (ru) Антитела и полипептиды, направленные против cd127
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
CL2012000520A1 (es) Anticuerpo o fragmento de union a antigeno del mismo capaz de unirse a dll4 humana; conjugado que comprende a dicho anticuerpo; vector aislado y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; y uso medico de dicho anticuerpo.
GT201300149A (es) Proteinas de union al tnf-a
PE20131376A1 (es) Anticuerpos para metaloproteinasa-9 de matriz
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
ES2528321T3 (es) Detección de a-fucosilación en anticuerpos
PE20141561A1 (es) Anticuerpos anti-lrp5 y metodos de uso
CO2019008675A2 (es) Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet
PE20131411A1 (es) Anticuerpos contra la tweak humana y usos de los mismos
BR112016014010A2 (pt) métodos para detectar anticorpos contra vírus da febre suína clássica tipo selvagem (csfv), para diferenciação entre animais infectados com csfv tipo selvagem e animais que foram vacinados contra csfv e para controlar uma infecção com csfv tipo selvagem, kit de teste de diagnóstico, e, uso de um carreador
CL2022000030A1 (es) Moléculas de unión a claudina-6 y usos de las mismas
AR084263A1 (es) Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen)
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)
PE20180576A1 (es) ANTICUERPOS MONOCLONALES ESPECIFICOS PARA EL ANTIGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, UTILES PARA LA DETECCION Y EL DIAGNOSTICO DE LA INFECCION CAUSADA POR VRSh
UY37082A (es) Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv